![](/img/cover-not-exists.png)
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance â¥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
Levin, Mark-David, Kater, Arnon, Mattsson, Mattias, Kersting, Sabina, Ranti, Juha, Thi Tuyet Tran, Hoa, Nasserinejad, Kazem, Niemann, Carsten UtoftVolume:
10
Journal:
BMJ Open
DOI:
10.1136/bmjopen-2020-039168
Date:
October, 2020
File:
PDF, 556 KB
2020